ETF Foundry
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.
profitability factor · long-only model fund

Foundry Healthcare ChTax Factor ETF

ETF Foundry Research (hypothetical) · rebalanced monthly

FCHHHYPOTHETICAL MODEL
Since ’99
−42%
Expense Ratio
0.45%
placeholder
Holdings
91
cap-weighted
Inception
Jun 2022
placeholder
Full Sharpe
-0.10
Ann. Return (LS)
-1.2%
Ann. Volatility
12.4%
Max Drawdown
-68.1%
Test Sharpe ’19–26
0.06
Test FF5 α (ann.)
-0.3%
vs Fama-French 5
Test FF5 α t-stat
-0.06
not significant
Monthly turnover
13%
of the long leg, per rebalance
Cumulative return (LS)
-42%
over 331 months
This fund holds the long leg only
Long leg Sharpe
0.68
what this fund holds
Long leg ann. return
10.9%
buyable, long-only
Long-short Sharpe
-0.10
requires shorting
Bottom bucket ann. return
12.1%
the basket shorted

Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.

Hypothetical growth of $1 — long-short backtest

Gross of the placeholder expense ratio and trading costs · not investor results

331 months

Holdings

Every constituent of the long leg — sort, search or filter by sector

91 of 91 · 100.0% of book
TickerCompanySectorMarket capWeight
1LLY
ELI LILLY & COHealthcare$1.11T
34.86%
2ABBV
ABBVIE INCHealthcare$449.63B
14.11%
3AMGN
AMGEN INCHealthcare$197.69B
6.21%
4ABT
ABBOTT LABORATORIESHealthcare$175.37B
5.50%
5GILD
GILEAD SCIENCES INCHealthcare$166.72B
5.23%
6BMY
BRISTOL MYERS SQUIBB COHealthcare$124.04B
3.89%
7VRTX
VERTEX PHARMACEUTICALS INCHealthcare$123.26B
3.87%
8SYK
STRYKER CORPHealthcare$122.63B
3.85%
9ISRG
INTUITIVE SURGICAL INCHealthcare$122.33B
3.84%
10REGN
REGENERON PHARMACEUTICALS INCHealthcare$70.94B
2.23%
11IDXX
IDEXX LABORATORIES INCHealthcare$44.76B
1.41%
12ALNY
ALNYLAM PHARMACEUTICALS INCHealthcare$35.71B
1.12%
13VEEV
VEEVA SYSTEMS INCHealthcare$31.74B
1.00%
14DXCM
DEXCOM INCHealthcare$29.58B
0.93%
15RMD
RESMED INCHealthcare$28.86B
0.91%
16ILMN
ILLUMINA INCHealthcare$28.24B
0.89%
17ROIV
ROIVANT SCIENCES LTDHealthcare$24.82B
0.78%
18MRNA
MODERNA INCHealthcare$24.53B
0.77%
19STE
STERIS PLCHealthcare$21.26B
0.67%
20NBIX
NEUROCRINE BIOSCIENCES INCHealthcare$17.18B
0.54%
21MEDP
MEDPACE HOLDINGS INCHealthcare$15.36B
0.48%
22SOLV
SOLVENTUM CORPHealthcare$14.08B
0.44%
23BTSG
BRIGHTSPRING HEALTH SERVICES INCHealthcare$13.71B
0.43%
24BAX
BAXTER INTERNATIONAL INCHealthcare$11.68B
0.37%
25PODD
INSULET CORPHealthcare$11.36B
0.36%
26EHC
ENCOMPASS HEALTH CORPHealthcare$11.13B
0.35%
27ARWR
ARROWHEAD PHARMACEUTICALS INCHealthcare$10.47B
0.33%
28TEM
TEMPUS AI INCHealthcare$9.42B
0.30%
29HALO
HALOZYME THERAPEUTICS INCHealthcare$9.23B
0.29%
30UHS
UNIVERSAL HEALTH SERVICES INCHealthcare$9.15B
0.29%
31HQY
HEALTHEQUITY INCHealthcare$8.17B
0.26%
32LQDA
LIQUIDIA CORPHealthcare$7.11B
0.22%
33LGND
LIGAND PHARMACEUTICALS INCHealthcare$6.08B
0.19%
34BLCO
BAUSCH & LOMB CORPHealthcare$5.80B
0.18%
35SHC
SOTERA HEALTH COHealthcare$5.06B
0.16%
36KNSA
KINIKSA PHARMACEUTICALS INTERNATIONAL PLCHealthcare$4.92B
0.15%
37LFST
LIFESTANCE HEALTH GROUP INCHealthcare$4.49B
0.14%
38MMSI
MERIT MEDICAL SYSTEMS INCHealthcare$4.41B
0.14%
39NVST
ENVISTA HOLDINGS CORPHealthcare$4.35B
0.14%
40DOCS
DOXIMITY INCHealthcare$3.94B
0.12%
41CPRX
CATALYST PHARMACEUTICALS INCHealthcare$3.85B
0.12%
42OGN
ORGANON & COHealthcare$3.55B
0.11%
43GRAL
GRAIL INCHealthcare$3.12B
0.10%
44XRAY
DENTSPLY SIRONA INCHealthcare$2.81B
0.09%
45TARS
TARSUS PHARMACEUTICALS INCHealthcare$2.58B
0.08%
46GRDN
GUARDIAN PHARMACY SERVICES INCHealthcare$2.57B
0.08%
47QURE
UNIQURE NVHealthcare$2.54B
0.08%
48LMAT
LEMAITRE VASCULAR INCHealthcare$2.32B
0.07%
49NEOG
NEOGEN CORPHealthcare$2.24B
0.07%
50MD
PEDIATRIX MEDICAL GROUP INCHealthcare$2.15B
0.07%
51ADMA
ADMA BIOLOGICS INCHealthcare$2.02B
0.06%
52ABCL
ABCELLERA BIOLOGICS INCHealthcare$1.97B
0.06%
53HRMY
HARMONY BIOSCIENCES HOLDINGS INCHealthcare$1.96B
0.06%
54ANIP
ANI PHARMACEUTICALS INCHealthcare$1.80B
0.06%
55IMCR
IMMUNOCORE HOLDINGS PLCHealthcare$1.78B
0.06%
56HROW
HARROW INCHealthcare$1.74B
0.05%
57HCSG
HEALTHCARE SERVICES GROUP INCHealthcare$1.74B
0.05%
58INVA
INNOVIVA INCHealthcare$1.60B
0.05%
59XERS
XERIS BIOPHARMA HOLDINGS INCHealthcare$1.52B
0.05%
60PNTG
PENNANT GROUP INCHealthcare$1.46B
0.05%
61AMN
AMN HEALTHCARE SERVICES INCHealthcare$1.36B
0.04%
62PAHC
PHIBRO ANIMAL HEALTH CORPHealthcare$1.35B
0.04%
63IRMD
IRADIMED CORPHealthcare$1.24B
0.04%
64AORT
ARTIVION INCHealthcare$1.22B
0.04%
65COLL
COLLEGIUM PHARMACEUTICAL INCHealthcare$1.17B
0.04%
66AVNS
AVANOS MEDICAL INCHealthcare$1.17B
0.04%
67NUTX
NUTEX HEALTH INCHealthcare$1.12B
0.04%
68CERT
CERTARA INCHealthcare$1.08B
0.03%
69BVS
BIOVENTUS INCHealthcare$1.01B
0.03%
70FBRX
FORTE BIOSCIENCES INCHealthcare$1.00B
0.03%
71TBPH
THERAVANCE BIOPHARMA INCHealthcare$873M
0.03%
72OMER
OMEROS CORPHealthcare$701M
0.02%
73CRMD
CORMEDIX INCHealthcare$661M
0.02%
74TCMD
TACTILE SYSTEMS TECHNOLOGY INCHealthcare$648M
0.02%
75MYGN
MYRIAD GENETICS INCHealthcare$584M
0.02%
76CTEV
CLARITEV CORPHealthcare$518M
0.02%
77XOMA
XOMA ROYALTY CORPHealthcare$504M
0.02%
78VMD
VIEMED HEALTHCARE INCHealthcare$466M
0.01%
79PRTA
PROTHENA CORP PUBLIC LTD COHealthcare$453M
0.01%
80DCTH
DELCATH SYSTEMS INCHealthcare$442M
0.01%
81PBYI
PUMA BIOTECHNOLOGY INCHealthcare$434M
0.01%
82CCRN
CROSS COUNTRY HEALTHCARE INCHealthcare$428M
0.01%
83CBIO
CRESCENT BIOPHARMA INCHealthcare$407M
0.01%
84ENTA
ENANTA PHARMACEUTICALS INCHealthcare$400M
0.01%
85SLP
SIMULATIONS PLUS INCHealthcare$369M
0.01%
86ELMD
ELECTROMED INCHealthcare$349M
0.01%
87VNDA
VANDA PHARMACEUTICALS INCHealthcare$327M
0.01%
88PDEX
PRO DEX INCHealthcare$183M
0.01%
89CUE
CUE BIOPHARMA INCHealthcare$126M
0.00%
90OPRX
OPTIMIZERX CORPHealthcare$126M
0.00%
91FRMM
FORUM MARKETS INCHealthcare$83M
0.00%

Full long-leg book as of July 2026 · cap-weighted · total market cap $3.19T. Hypothetical model holdings — not a registered fund’s portfolio.

Sector Breakdown

1 sectors
Healthcare
100.0%

Portfolio Style

Size × value map of the long-leg book

91 classified
Value
Blend
Growth
Large
Mid
Small
13%7
24%14
60%17
1%9
<1%5
1%10
<1%9
<1%9
<1%2

Share of long-leg capital by market cap × book-to-market, using terciles of the 499-name universe at July 2026. Rows: Large ≥ $3.6B, Small < $964M. Columns: Value ≥ 0.67, Growth < 0.37 B/M. The dot marks the capital-weighted centroid of the book — 99% toward Large, 74% toward Growth. +1% unclassified (9 missing size/value). Hypothetical holdings — descriptive, not realized P&L.

Tilt over time
Size tilt99% → Large
SmallLarge
Value ↔ growth tilt74% → Growth
ValueGrowth

Capital-weighted centroid of the long leg, December 1998July 2026; the right-hand end is the same value as the box’s dot. 91 names now. The faded start covers early months with a much thinner universe. Hypothetical holdings — descriptive, not P&L.

Constraint checks

How this book measures against the concentration and liquidity rules — as implemented here

How this book was built

These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.

Passed
3
Failed
3
Not tested
1
Independent checks
7

7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.

1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.

  • With respect to 75% of total assets, no more than 5% may be invested in the securities of any one issuer.

    Required
    >= 75.0%
    Actual
    59.1%
    Margin
    -15.9%
  • No more than 25% of total assets may be invested in the securities of any one issuer.

    Required
    <= 25.0%
    Actual
    34.9%
    Margin
    -9.9%
  • Days required to liquidate the largest position at 20% of one day's dollar volume.

    Required
    <= 7.0 days
    Actual
    unbounded
    Margin
Reported separately — arithmetically implied

Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.

No verdict sits within 1.0pp of its limit.

Data version — panel=20260719T025334 rows=2239262 asof=202607 issuers=20260719T014536 rates=20260804T224700

Measured on the 2026-07 formation date across 91 holdings (cap-weighted). A different formation date can produce different verdicts.

Derivatives risk (Rule 18f-4)

Whether this long-only book is subject to the VaR tests at all

This assessment describes the long-only book this fund holds — the top bucket only.

Governing rule
Rule 18f-4(c)(4) limited derivatives user exception

This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.

Limited derivatives user exceptionby construction

Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.

Qualifies
Required
<= 10% of net assets
Exposure
0% of net assets
Margin
+10pp

No confidence interval: this follows from portfolio construction, not from an estimate.

Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.

Informational — does not govern

This fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.

Measured
1.1 (95% CI 0.8-1.3)
x reference VaR
Limit
2.00x
<= 2.00x reference VaR
Fund VaR
11.0%
99% / 20d
Reference
9.6%
FF5 market (mkt)

historical method · 331 monthly observations · about 3.3 in the 99% tail · paired percentile bootstrap over months

Same test, three estimators
historical
1.14x
within
parametric
0.99x
within
cornish fisher
0.92x
within

The estimators differ materially in value but agree on the verdict. Historical and Gaussian fund VaR differ by 15%; both still land on the same side of the 2x limit.

Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.

The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.

See the long-short verdict on the factor page →

Since publication

Did the edge survive the paper coming out?

published 2011
Before publication (pre-2011)
-0.22
Sharpe · -2.7% p.a.
January 1999December 2011 · 156 mo
Since publication
0.01
Sharpe · 0.1% p.a.
January 2012July 2026 · 175 mo
Change in Sharpe+0.23the return flipped from negative to positive since publication

Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.

Consistency across eras

Is this record broadly durable, or one regime?

26 windows
Positive windows
31%
8 of 26 3-year windows made money
Worst window
-1.06
Sharpe, January 2006 – December 2008
January 1999July 2026
Median Sharpe
-0.13
Dispersion
0.41
Best window
0.93

3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.

Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.

Returns

Long leg is what this fund holds — long-short is shown for reference

since January 1999
Trailing
PeriodLong legLong-short
1 yearcum.36.9%-2.3%
3 yearsp.a.16.1%8.5%
5 yearsp.a.5.4%-2.1%
10 yearsp.a.10.1%0.2%
Since inceptionp.a.10.0%-2.0%
Calendar years
YearLong legLong-short
20267 mo8.4%-13.2%
202526.8%18.8%
20248.7%12.9%
20234.1%12.3%
2022-14.9%-22.1%
202120.6%-5.1%
202014.5%5.2%
201914.9%-4.1%
20187.3%2.8%
201724.0%0.4%
2016-7.7%-7.2%
20155.4%-4.9%
201429.7%1.7%
201341.4%-2.2%
201219.4%2.4%
201114.7%-1.9%
20100.8%-12.6%
200929.0%0.5%
2008-13.5%-4.2%
20074.9%-2.0%
2006-3.9%-15.3%
200513.6%3.9%
200410.8%13.8%
200333.3%-16.8%
2002-27.2%-5.0%
2001-9.2%-1.0%
200044.6%-17.0%
199913.4%21.1%

Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through July 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.

Fund Facts

Ticker (pseudo)FCHH
IssuerETF Foundry Research (hypothetical)
SeriesHypothetical Model Portfolio Series (not a registered trust)
Expense ratio0.45% (placeholder)
Inception2022-06-09 (placeholder)
Listing exchangeNot listed (hypothetical)
CUSIPNot applicable (hypothetical model portfolio)
RebalanceMonthly
Holdings as ofJuly 2026
Total mkt cap (long leg)$3.19T

Methodology

The Foundry Healthcare ChTax Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a ChTax signal and holds the top quintile with the highest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.

This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.

Documents (draft — hypothetical)

Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.

Summary Prospectus

Objective, fees, strategy, and key risks.

View →
Prospectus

Full strategy, model methodology, and risks.

View →
Statement of Additional Information

Policies, construction, and governance.

View →
Fact Sheet

One-page snapshot with top holdings.

View →
Daily Holdings

Full current constituent list.

View →

DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.